Picture of Amicus Therapeutics logo

FOLD — Amicus Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

Amicus Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

* Amicus Therapeutics Inc  FOLD.OQ  reported a quarterly
adjusted
loss of 16 cents​​ per share for the quarter ended in March,
higher than the same quarter last year, when the company
reported EPS of -18 cents.  The mean expectation of
eleven analysts for the quarter was for a loss of 7 cents per
share. Wall Street expected results to range from -10 cents
to -3 cents per share.
    * Revenue rose 28% to $110.40 million from a year ago;
analysts
expected $111.19 million. 
    * Amicus Therapeutics Inc's reported EPS for the quarter was
a
loss of 16 cents​.
    * The company reported a quarterly loss of $48.42 million.
    * Amicus Therapeutics Inc shares had fallen by 13.9% this
quarter and lost 28.5% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 27.5%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Amicus
Therapeutics Inc is $20.00 
This summary was machine generated from LSEG data May 9 at 01:32
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.07          -0.16          Missed
 Dec. 31 2023      -0.06          -0.11          Missed
 Sep. 30 2023      -0.08          -0.07          Beat
 Jun. 30 2023      -0.12          -0.15          Missed

Recent news on Amicus Therapeutics

See all news